Aortic Valvuloplasty as a Bridge to TAVR: Are We Wasting Our Time?

Doing a balloon aortic valvuloplasty can be a good way to “buy” time before a transcatheter aortic valve replacement (TAVR), according to a registry to be published this week in J Am Coll Cardiol Intv.

Valvuloplastia aórtica como puente al TAVI

This study analyzed the database of a whole country to find out the incidence, predictors and outcomes of balloon aortic valvuloplasty as a bridge to TAVR in the daily clinical practice. 

Of 3691 patients receiving balloon aortic valvuloplasty between 2015 and 2016, 1426 subsequently received TAVR. TAVR was prior discharge in 7.4%, within 30 days in 35%, between 31 and 90 days in 47%, between 91 and 180 days in 14%, and over 180 days in 4% of patients.

Negative predictors of valvuloplasty patients reaching TAVR (before or after) resulted quite logical and expected. A history of defibrillation, dementia, malnutrition, and severe comorbidities predicted patients would not get to TAVR.


Read also: Tricuspid valve: Is Percutaneous Intervention Feasible in Patients with Definite Pacemaker?


When comparing patients with direct access to TAVR vs. balloon valvuloplasty patients, they found inhospital mortality was practically identical (3.7% vs 3.5% after propensity score matching; p=0.91).

Major complications, hospital-stay and discharge conditions also resulted similar, even though costs increased for those who went directly to TAVR.

Conclusion

In this contemporary registry of the daily practice, up to 40% of patients with severe aortic stenosis received balloon aortic valvuloplasty as bridge to TAVR. Most of them within 90 days. 

Outcomes between those undergoing TAVR directly and those with prior valvuloplasty were similar, which makes it adequate to “buy” time before the end goal. 

Original Title: Balloon Aortic Valvuloplasty as a Bridge to Aortic Valve Replacement A Contemporary Nationwide Perspective.

Reference: Akram Kawsara et al. J Am Coll Cardiol Intv 2020, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...